**Supplement. Definitions for Exposure Variables and Covariates Used in Descriptive Analyses and Statistical Models**

|  |  |
| --- | --- |
| **Exposure Variables** |  |
| Angiotensin converting enzyme inhibitors (ACEIs) | Current use defined as having a dispensing with a days’ supply estimated to last until on or beyond 2/29/2020. Benazepril (e.g., Lotensin)Captopril (e.g., Capoten, Capozide)Enalapril (e.g., Vaseretic, Vasotec)Lisinopril (e.g., Prinivil, Zestril)QuinaprilRamipril (e.g., Altace) |
| Angiotensin receptor blockers | Current use defined as having a dispensing with a days’ supply estimated to last until on or beyond 2/29/2020. Candesartan (e.g., Atacand)Irbesartan (e.g., Avalide, Avapro)Losartan (e.g., Cozaar, Entresto, Hyzaar)Olmesartan (e.g., Azor, Benicar)Telmisartan (e.g., Micardis)Valsartan (e.g., Diovan) |
| **Covariates – Medication Use** |  |
| Insulin  | Current use defined as having at least one dispensing in the 90 days prior to 2/29/2020. AspartDegludecDetemirLisproGlargineGlulisineNPHRegular  |
| Prednisone | Current use defined as having at least one dispensing in the 90 days prior to 2/29/2020.  |
| Loop diuretics | Current use defined as having a dispensing with a days’ supply estimated to last until on or beyond 2/29/2020. BumetanideEthacrynic acidFurosemide |
| Thiazide diuretics | Current use defined as having a dispensing with a days’ supply estimated to last until on or beyond 2/29/2020. HydrochlorothiazideChlorthalidone |
| Calcium channel blockers | Current use defined as having a dispensing with a days’ supply estimated to last until on or beyond 2/29/2020. AmlodipineDiltiazemFelodipineIsradipineNicardipineNifedipineNimodipineNisoldipineVerapamil |
| Beta blockers | Current use defined as having a dispensing with a days’ supply estimated to last until on or beyond 2/29/2020. AcebutololAtenololBetaxalolBisoprololCarteololCarvedilolEsmololLabetalolLevobunololMetoprololMetripranololNadololNebivololPenbutololPindololPropranololSotalolTimolol |
| **Covariates: Chronic illnesses** |  |
| Diabetes | ICD-10 codes: E10.10-E10.11E10.2-E10.5E10.51-E10.52E10.59 E10.61-E10.619E10.641E10.65 E10.69 E10.9  E11.00-E11.01 E11.2-E11.5E11.51-E11.52 E11.59 E11.61-E11.619E11.641E11.65 E11.69 E11.9  E13.00-E13.01 E13.10-E13.11 E13.2-E13.5E13.51-E13.52 E13.59 E13.61-E13.619E13.641E13.9   |
| Prior myocardial infarction | ICD-10 codes: I21-I22.9I25.2  |
| Heart failure | ICD-10 codes: I50-I50.999 |
| Renal disease | ICD-10 codes: N03.0-N03.9  N05.2-N05.5  N05.9  N06.2-N06.5  N07.2-N07.5  N08    N17.1-N17.2  N18.1-N18.6  N18.9  N19    N25.0  N25.1  N25.81 N25.89 N25.9   |
| Malignancy | ICD-10 codes: C00-C26.999C30-C34.999C37-C41.999C43-C43.999C45-C45.7 C46-C58.999C60-C76.999C81-C85.999C86-C86.999C88-C88.999C90-C97.999D03.0  D03.10-D03.12 D03.20-D03.22 D03.30 D03.39 D03.4  D03.51-D03.52 D03.59 D03.60-D03.62 D03.70-D03.72 D03.8  D03.9  D45     |
| Hypertension | ICD-10 codes: I10I11.0I11.9I12.0I12.9I13.0I13.10I13.11I13.2I13.4I15.0I15.1I15.2I15.8I15.9I16.0I16.1I16.3I16.9I67.4O10.011O10.012O10.013O10.019O10.02O10.03O10.113O10.211O10.413O10.42O10.911O10.912O10.913O10.919O10.92O10.93O11.3O11.4O11.5O11.9O13.1O13.2O13.3O13.5O13.9O16.1O16.2O16.4O16.5O16.9 |
| Asthma  | ICD-10 codes: J45.xxx |
| Chronic obstructive pulmonary disease  | ICD-10 codes: J41.xxx, J42.xxx, J43.xxx, J44.xxx, J47.xxx  |
| Indication for ACEI/ARB use | DiabetesHypertensionHeart failurePrior myocardial infarction |
| Charlson score | Defined based on Klabunde implementation; includes outpatient visits. Conditions included: DiabetesDiabetes with chronic complicationsPrior myocardial infarctionPeripheral vascular diseaseCerebrovascular diseaseHeart failureDementiaChronic pulmonary diseaseRheumatologic diseaseMild liver diseaseModerate/severe liver diseaseHemiplegia/paraplegiaPeptic ulcer diseaseRenal diseaseMalignancy including leukemia/lymphomaMetastatic solid tumorHIV/AIDS |
| **Other Covariates** | All obtained from KPWA electronic health data |
| Current tobacco use |  |
| Body mass index |  |
| Race/ethnicity |  |
| Age |  |
| Sex |  |